Reaction Details |
| Report a problem with these data |
Target | Cytochrome P450 4B1 |
---|
Ligand | BDBM330295 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_2078100 (CHEMBL4733891) |
---|
IC50 | >30000±n/a nM |
---|
Citation | Xiang, HY; Wang, X; Chen, YH; Zhang, X; Tan, C; Wang, Y; Su, Y; Gao, ZW; Chen, XY; Xiong, B; Gao, ZB; Chen, Y; Ding, J; Meng, LH; Yang, CH Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors. Eur J Med Chem209:0 (2021) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Cytochrome P450 4B1 |
---|
Name: | Cytochrome P450 4B1 |
Synonyms: | 1.14.14.1 | CP4B1_HUMAN | CYP4B1 | CYPIVB1 | Cytochrome P450 4B1 | Cytochrome P450-HP |
Type: | PROTEIN |
Mol. Mass.: | 59005.59 |
Organism: | Homo sapiens |
Description: | ChEMBL_119703 |
Residue: | 511 |
Sequence: | MVPSFLSLSFSSLGLWASGLILVLGFLKLIHLLLRRQTLAKAMDKFPGPPTHWLFGHALE
IQETGSLDKVVSWAHQFPYAHPLWFGQFIGFLNIYEPDYAKAVYSRGDPKAPDVYDFFLQ
WIGRGLLVLEGPKWLQHRKLLTPGFHYDVLKPYVAVFTESTRIMLDKWEEKAREGKSFDI
FCDVGHMALNTLMKCTFGRGDTGLGHRDSSYYLAVSDLTLLMQQRLVSFQYHNDFIYWLT
PHGRRFLRACQVAHDHTDQVIRERKAALQDEKVRKKIQNRRHLDFLDILLGARDEDDIKL
SDADLRAEVDTFMFEGHDTTTSGISWFLYCMALYPEHQHRCREEVREILGDQDFFQWDDL
GKMTYLTMCIKESFRLYPPVPQVYRQLSKPVTFVDGRSLPAGSLISMHIYALHRNSAVWP
DPEVFDSLRFSTENASKRHPFAFMPFSAGPRNCIGQQFAMSEMKVVTAMCLLRFEFSLDP
SRLPIKMPQLVLRSKNGFHLHLKPLGPGSGK
|
|
|
BDBM330295 |
---|
n/a |
---|
Name | BDBM330295 |
Synonyms: | Methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate | US9724352, I-33 |
Type | Small organic molecule |
Emp. Form. | C24H29F3N8O5S |
Mol. Mass. | 598.598 |
SMILES | COC(=O)Nc1cc(c(cn1)-c1nc(N2CCOCC2)c2cc(CN3CCN(CC3)S(C)(=O)=O)cn2n1)C(F)(F)F |
Structure |
|